Favorable Media Coverage Somewhat Unlikely to Affect Luminex Corporation (LMNX) Share Price
News articles about Luminex Corporation (NASDAQ:LMNX) have trended positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Luminex Corporation earned a news impact score of 0.28 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 46.9105300646441 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Luminex Corporation (LMNX) opened at 18.95 on Friday. Luminex Corporation has a 12-month low of $17.64 and a 12-month high of $23.62. The company has a 50-day moving average price of $20.30 and a 200-day moving average price of $19.62. The firm has a market cap of $835.15 million, a P/E ratio of 58.67 and a beta of 0.29.
Luminex Corporation (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.11. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The company had revenue of $76.50 million for the quarter, compared to analysts’ expectations of $75.45 million. During the same quarter in the prior year, the business posted $0.33 EPS. The business’s revenue was up 19.2% compared to the same quarter last year. On average, analysts predict that Luminex Corporation will post $0.54 earnings per share for the current year.
A number of research firms have recently issued reports on LMNX. ValuEngine raised shares of Luminex Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, May 11th. Zacks Investment Research downgraded Luminex Corporation from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Jefferies Group LLC restated a “hold” rating and issued a $21.00 price objective on shares of Luminex Corporation in a report on Friday, June 9th. BidaskClub downgraded Luminex Corporation from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. Finally, TheStreet downgraded Luminex Corporation from a “b” rating to a “c+” rating in a report on Monday, August 7th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. Luminex Corporation has an average rating of “Hold” and an average target price of $21.60.
ILLEGAL ACTIVITY NOTICE: “Favorable Media Coverage Somewhat Unlikely to Affect Luminex Corporation (LMNX) Share Price” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/19/favorable-media-coverage-somewhat-unlikely-to-affect-luminex-corporation-lmnx-share-price.html.
In related news, Director G Walter Loewenbaum II sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $20.23, for a total transaction of $505,750.00. Following the transaction, the director now directly owns 738,896 shares of the company’s stock, valued at approximately $14,947,866.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by insiders.
Luminex Corporation Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.